Docetaxel Use Associated With Significant Reduction in Prostate Cancer Death in Very Poor Prognostic Group
A meta-analysis of five prospective randomized clinical trials (RCTs) found that adding docetaxel to standard-of-care (SOC) treatment was associated with a 70% reduction in death from prostate cancer-specific mortality (PCSM).
Source: BWH News - Category: Hospital Management Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Docetaxel | Hospital Management | Prostate Cancer | Taxotere